Finally, this is the first study to demonstrate that serum FSTL3 level partially mediates the association of increased NAFLD fibrosis risk and AMI in patients with T2DM and co-existent NAFLD. The gene discussed is FSTL3; the disease is type 2 diabetes mellitus.